Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774282 | 1.00 | MMP9 (0.47) | MMP9MMP8MMP1TRPM8MAPT | |
| SCHEMBL19602425 | 0.82 | MMP9 (0.52) | MMP9MMP8MMP1TRPM8MAPT | |
| SCHEMBL18307298 | 0.80 | KMT2A (0.44) | MEN1KMT2AALDH1A1ANPEPTHRB | |
| SCHEMBL24814077 | 0.80 | MMP9 (0.53) | MMP9MMP8MMP1TRPM8MAPT | |
| SCHEMBL30751663 | 0.80 | MMP9 (0.53) | MMP9MMP8MMP1TRPM8MAPT | |
| SCHEMBL5413934 | 0.79 | KMT2A (0.43) | MAPTL3MBTL1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL1109144 | 0.79 | KMT2A (0.43) | MAPTL3MBTL1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL5413928 | 0.79 | KMT2A (0.43) | MAPTL3MBTL1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL12379297 | 0.79 | KMT2A (0.43) | MAPTL3MBTL1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL1105488 | 0.79 | KMT2A (0.43) | MAPTL3MBTL1KMT2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546383-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-8350034-B2 | Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-09-13 | — | — | US | disclosed |
| EP-1831226-B1 | CHIRAL TETRACYCLIC COMPOUNDS INDUCING INTERFERON BIOSYNTHESIS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1831221-B1 | SUBSTITUTED CHIRAL FUSED 1,2 IMIDAZO 4,5-C RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8207162-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110293654-A1 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMANY | 2011-12-01 | — | — | US | disclosed |
| US-8034938-B2 | Imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a CH( R1) group in the fused ring at 1-position of imidazo ring; modulate immune response, by induction of cytokine biosynthesis or other mechanism | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-7943609-B2 | Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides | 3M INNOVATIVE PROPRERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080085895-A1 | Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | IFNAR1, IFNG, IL4 | MMP9 4695/4885MMP8 3055/4885MMP1 4357/4885 |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | MMP9 4698/4885MMP8 3130/4885MMP1 4345/4885 |
| US-20110293654-A1 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IL4, IFNAR1 | MMP9 4841/4885MMP8 4223/4885MMP1 4658/4885 |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | MMP9 4695/4885MMP8 3055/4885MMP1 4357/4885 |
| US-20080085895-A1 | Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | IFNG, IL4, IFNAR1 | MMP9 4841/4885MMP8 4223/4885MMP1 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.